Bayer's Jadelle to be listed in New Zealand

26 September 2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with Bayer New Zealand, the local subsidiary of German pharma major Bayer (BAYN: DE) for the listing and supply of Jadelle (levonorgestrel 2 x 75 mg rods). This was the subject of a consultation letter dated August 29, 2014.

Jadelle will continue to be listed in Section B and Part II of Section H of the Pharmaceutical Schedule at the following price and subsidy (ex-manufacturer, excluding GST). The product will be priced at NZ133.65 ($105.48).

Jadelle will be the sole subsidized hormonal long-acting reversible contraceptive in the progesterone-only contraceptives, Contraceptives – Hormonal sub-group on the Genito-Urinary System of Section B and Part II of Section H of the Pharmaceutical schedule from October 1, 2014 until December 31, 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK